Each 1-hour session will include 4 topic modules focused on the current management of biologically defined subsets of NSCLC and emerging research information on novel agents and strategies under active investigation. Each module will employ an identical format and include:

• Audience Polling Using Keypad Devices
• Display of Steering Committee Responses to Related Clinical Questions
• Faculty Review of Select Data Sets

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS AND PARTICIPATING FACULTY

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of NSCLC.

Learning Objectives:

• Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis for patients with metastatic NSCLC, and use this information to implement a comprehensive approach to genomic assessment.
• Use mutation status, clinical characteristics and tumor histology to appropriately prioritize front-line and subsequent treatment approaches for patients with metastatic NSCLC.
• Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the long-term management of EGFR mutation-positive NSCLC, and discern how novel EGFR tyrosine kinase inhibitors can be optimally administered to patients with progressive EGFR mutation-positive disease.
• Communicate the efficacy and safety of approved and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK mutation testing.
• Recall existing and emerging research information demonstrating the efficacy and safety of anti-PD-1/PD-L1 antibodies for patients with squamous and nonsquamous metastatic NSCLC, and use this information to guide treatment planning.
• Recall the design of ongoing clinical trials evaluating novel investigational agents in NSCLC, and counsel appropriately selected patients about availability and participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
These activities are supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Merck.